Biopharmaceutical News and Research

RSS

Soligenix first quarter revenues decrease to $647,418

Soligenix, Inc., a development stage biopharmaceutical company, announced today its financial results for the quarter ending March 31, 2012.

14 May 2012

S1 Biopharma announces foray into male sexual health with S1P-205

S1 Biopharma, an early-stage biopharmaceutical company developing therapeutic solutions for Hypoactive Sexual Desire Disorder (HSDD) and related sexual dysfunctions, today announced its foray into male sexual health with S1P-205, the first and only drug in development for male HSDD.

14 May 2012

3SBio first quarter total net revenues increase 24.5% to RMB147.2M

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced its unaudited financial results for the first quarter ended March 31, 2012.

14 May 2012

BioTrends tracks uptake of Yervoy and Zelboraf for advanced melanoma

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, has released findings from the second wave of its LaunchTrends® Yervoy and Zelboraf report, in which 103 U.S.-based medical oncologists were surveyed about their current and expected treatment patterns in advanced melanoma.

11 May 2012

Newly diagnosed schizophrenia patients continue to use oral Abilify as first-line therapy

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that analysis of U.S. longitudinal patient-level claims data reveals the use of Bristol-Myers Squibb's oral Abilify as a first-line therapy for newly diagnosed schizophrenia patients continues to grow.

10 May 2012

Orexigen reports net loss of $10.4 million for first quarter 2012

Orexigen Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the first quarter of 2012.

10 May 2012

Provectus announces final data from PV-10 Phase 2 trial on metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that Phase 2 final data on PV-10 for metastatic melanoma will be presented at the 2nd European PostASCO Melanoma Meeting 2012, Interdisciplinary Global Conference on Developing New Treatments for Melanoma, on June 22, 2012, in Munich, Germany.

9 May 2012

BioDiem announces new vaccine research collaboration with French-based VIVALIS

Australian vaccine development company BioDiem Ltd (ASX: BDM) today announced that it has begun a research collaboration with France-based VIVALIS (Euronext code: VLS), a biopharmaceutical company with expertise in vaccine production technologies.

9 May 2012

ACADIA first quarter net loss increases to $6.2 million

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the first quarter ended March 31, 2012.

9 May 2012

Maxygen first quarter net loss increases to $2.6 million

Maxygen, Inc., a biopharmaceutical company, today announced financial and business results for the quarter ended March 31, 2012.

8 May 2012

Intellect Neurosciences announces two new programs in Alzheimer's disease development pipeline

Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of tau protein, which Intellect intends to develop for therapeutic and diagnostic uses.

7 May 2012

Unigene first quarter net loss decreases to $6.0 million

Unigene Laboratories, Inc., today announced financial results for the first quarter ended March 31, 2012.

7 May 2012

Lexicon first quarter revenues decrease 50% to $0.3 million

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months ended March 31, 2012.

3 May 2012

Johnson & Johnson announces acquisition of Bioseal

Johnson & Johnson (China) Investment Ltd. today announced it has acquired Guangzhou Bioseal Biotechnology Co., Ltd. (Bioseal) a privately held biopharmaceutical company specializing in the design, development and commercialization of a porcine plasma-derived biologic product for controlling bleeding during surgery.

3 May 2012

Probiodrug AG, collaborators explain interplay of key suspects in Alzheimer’s

Probiodrug AG (Probiodrug), a biotech company developing products for the treatment of neurodegenerative and inflammatory diseases with a particular focus on Alzheimer's disease (AD), today announced its scientists and academics collaborators published seminal findings on the role of pyroglu Aβ in AD pathology in the May 2, 2012 online edition of the journal Nature (DOI: 10.1038/nature11060). The new findings add to the growing body of evidence that pyroglu Aβ plays a crucial role in the initiation of AD. In addition, the research results further elucidate the mechanism by which pyroglu Aβ triggers neuronal toxicity.

3 May 2012

Novo Nordisk granted exclusive rights to Caisson's heparosan-based drug delivery technology

Caisson Biotech, L.L.C., a biopharmaceutical company with a patented heparosan-based drug delivery technology, announced today that it has entered into a Development and License Agreement with Novo Nordisk A/S, a global healthcare company and leader in diabetes care.

From Novo Nordisk 2 May 2012

AmerisourceBergen acquires World Courier Group

AmerisourceBergen Corporation today announced that it has completed the previously announced acquisition of World Courier Group, Inc., a privately held leading global specialty transportation and logistics provider for the biopharmaceutical industry.

2 May 2012

Enrollment complete in Zalicus Synavive Phase 2b clinical trial for rheumatoid arthritis

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced it has completed enrollment with 292 patients enrolled in the SYNERGY trial, a Phase 2b clinical trial designed to evaluate the safety and efficacy of Synavive, a low-dose glucocorticoid with the potential for amplified immuno-inflammatory benefits, in patients with rheumatoid arthritis (RA).

30 Apr 2012

Tolero granted exclusive global rights to commercialize MannKind's novel BTK compounds

Tolero Pharmaceuticals and MannKind Corporation today announced a license agreement granting Tolero exclusive worldwide rights to develop and commercialize compounds from MannKind's novel BTK (Bruton's tyrosine kinase) program, which are currently being developed for the treatment of hematological malignancies and inflammatory diseases.

30 Apr 2012

Positive top-line results from Shire’s Vyvanse Phase 2 study on binge eating disorder

Shire plc, the global specialty biopharmaceutical company, today announced positive top-line results from a Phase 2 study to evaluate the safety and efficacy of Vyvanse (lisdexamfetamine dimesylate) Capsules, (CII) in adults with binge eating disorder.

27 Apr 2012